Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from TG rapeutics

Biotech Growth Stock Boosted By FDA Approval For Multiple Sclerosis Treatment

Growth stock TG Therapeutics has surged 80% after FDA approval for its multiple sclerosis treatment.

Investors Business Daily

5 Analysts Have This to Say About TG Therapeutics

5 Analysts Have This to Say About TG Therapeutics

Analysts have provided the following ratings for TG Therapeutics (NASDAQ:TGTX) within the last quarter:

Peering Into TG Therapeutics's Recent Short Interest

Peering Into TG Therapeutics's Recent Short Interest

TG Therapeutics's (NASDAQ:TGTX) short percent of float has fallen 8.05% since its last report. The company recently reported that it has 19.37 million shares sold short, which is 14.63% of all regular shares that are available for trading.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

12 Health Care Stocks Moving In Friday's Intraday Session

Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022

What 4 Analyst Ratings Have To Say About TG Therapeutics

Over the past 3 months, 4 analysts have published their opinion on TG Therapeutics (NASDAQ:TGTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Expert Ratings for TG Therapeutics

TG Therapeutics (NASDAQ:TGTX) has observed the following analyst ratings within the last quarter:

inkl

Read news from The Economist, FT, and more,
with one subscription

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Monday's Intraday Session

Why TG Therapeutics Stock Is Plunging Today

Why TG Therapeutics Stock Is Plunging Today

TG Therapeutics Inc (NASDAQ: TGTX) shares are trading significantly lower Monday morning after the company announced it has voluntarily withdrawn the pending Biologics License Application/supplemental New Drug Application for the combination of ublituximab and UKONIQ for the treatment of

Looking Into TG Therapeutics's Return On Capital Employed

Looking Into TG Therapeutics's Return On Capital Employed

TG Therapeutics (NASDAQ:TGTX) brought in sales totaling $2.32 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 8.99%, resulting in a loss of $93.34 million.

Organisations

B of A Securities

Ollie Bargain Outlet

Hewlett Packard

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Multiple Sclerosis

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play